ADVANCE ONLINE PUBLICATION
A SNIPpet of safety: a Goldilocks approach in CAR-T therapy
Mehdi Benzaoui1,2 , Naomi Taylor1,2,* , Nirali N. Shah1,*1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Despite the remarkable efficacy of chimeric antigen receptor (CAR) T-cells in B-cell malignancies, their full potential in solid tumors has not yet been achieved. In a recent publication in Cell , Labanieh et al. developed a druggable CAR T-cell construct that allows optimal fine-tuning of CAR T-cells to achieve maximal efficacy and reduce toxicity.